[The effect of etiroxate on serum lipids after myocardial infarction or in angina pectoris].
The lipid-lowering effect of etiroxate was studied in a double-blind cross-over trial comprising 183 patients with hyperlipoproteinaemia, most of whom had suffered myocardial infarction or exhibited confirmed coronary insufficiency. Etiroxate (40 mg daily) and placebo were administered for a period of 12 weeks each. In approximately 60% of the cases with Type IIa/IIb hyperlipoproteinaemia the cholesterol level fell by more than 10%. As regards the frequency of heart complaints, the consumption of nitroglycerine capsules, and heart rate, there were no statistically significant differences between the placebo and etiroxate phases. Thus etiroxate did not have any unfavourable cardiac side-effects in the patients of this study. No negative effects on hepatic and renal function or the peripheral blood count were observed.
D000787:Angina Pectoris / Q000097:blood* / Q000150:complications; D001777:Blood Coagulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D006321:Heart / Q000187:drug effects; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008099:Liver / Q000187:drug effects; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood*; D010919:Placebos; D013974:Thyroxine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010919:Placebos; D014280:Triglycerides; C010150:etiroxate; D013974:Thyroxine
Wirkung von Etiroxat auf die Lipide des Blutes nach Herzinfarkt bzw. bei Angina pectoris